Individualized treatment with sunitinib versus standard dosing with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).Naveen S. Basappa, Daniel Yick Chin Heng, Sebastién J. Hotte et al.|Journal of Clinical Oncology|2017Cited by 6
Efficacy of targeted therapy (TT) after checkpoint inhibitors (CPI) in metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer Information System (CKCis).Austin Kalirai, Naveen S. Basappa, Lori Wood et al.|Journal of Clinical Oncology|2019Cited by 3
Efficacy of tyrosine kinase inhibitors (TKI) after combination ipilimumab plus nivolumab (I/N) in metastatic clear cell renal cell carcinoma (ccmRCC) patients: Results from the Canadian Kidney Cancer Information System (CKCis).Austin Kalirai, Naveen S. Basappa, Isaiah Joy et al.|Journal of Clinical Oncology|2022Cited by 0
Individualized treatment with sunitinib versus standard dosing with sunitinib or pazopanib in patients with metastatic renal cell carcinoma (mRCC): Results from the Canadian Kidney Cancer information system (CKCis).Naveen S. Basappa, Daniel Yick Chin Heng, Aly‐Khan A. Lalani et al.|Journal of Clinical Oncology|2017Cited by 0